北美综合征多重诊断市场 - 按产品和服务（试剂和消耗品、仪器、软件和配件及服务）、感染类型（病毒、细菌、寄生虫和真菌）、疾病（呼吸道感染、胃肠炎、性传播感染、败血症、脑膜炎等）、小组类型（呼吸道小组、胃肠道小组、性传播疾病小组、血液败血症小组、脑膜炎小组等）、最终用户（临床实验室、医院、制药和生物技术公司、研究机构等）行业趋势和预测到 2029 年。
市场定义和见解
共振多功能诊断用于检测呼吸道感染、感染等传染病的高级诊断测试肠胃炎性传染疾病、败血症、脑膜炎等。 综合多功能诊断还帮助临床医生或医院检测出各类疾病的症状和征兆. 这使保健提供者能够为病人提供正确的治疗,并提供更精确的结果和可以更快地进行的护理。
共振多子测试用于同时诊断出许多病原体. 在合成多ex诊断中,使用各种试剂和消耗品以及仪器和配件,这有助于保持准确性并提供快速诊断结果. 这些多功能测试被快速诊断出存在某些感染,使得临床管理决定能够被迅速作出. 基于多功能技术的测试被称为测试面板. 用于合成测试的面板被设计为诊断与同型或同型综合征有关的多种疾病. 这些小组有助于在护理时评估疾病的原因。 胃肠道板和呼吸道板是合成板的种类.
Syndromic多ex测试利用了多ex PCR的先进技术,在Syndromic多ex诊断中使用的多面板的帮助下,提供准确而快的诊断结果,在一小时内提供诊断结果. 新一代的合成多肽能迅速识别出呼吸道标本中常见的病原体类型,血液和脑脊髓. 使用多面板与更快的周转时间、减少其他不必要的实验室测试、更快的诊断和有针对性的治疗有关。
数据桥市场研究分析认为,在2022至2029年的预测期间,北美合成多功能诊断市场将以9.0%的CAGR增长.
|
报表计量 |
细节 |
|
预测期 |
2022至2029年统计 |
|
基准年 |
2021 |
|
历史年代 |
2020 |
|
数量单位 |
单位:单位:单位,定价 |
|
覆盖部分 |
产品和服务(试剂和消耗品、仪器、软件和辅助用品和服务)、感染类型(病毒、细菌、寄生虫和真菌)、疾病(呼吸道感染、肠胃炎、性传播感染、塞普西、门宁炎等)、小组类型(呼吸小组、GI-Enteric小组、性传播疾病小组、血液-塞普西)小组讨论会(临床实验室、医院、制药和生物技术公司、研究所等) |
|
涵盖国家 |
美国、加拿大和墨西哥 |
|
覆盖的市场玩家 |
生物火诊断(BioMérieux SA的子公司)、Seegene公司(韩国)、Luminex公司。 A DiaSorin公司(美国)、F.Hoffmann-La Roche有限公司(瑞士)、BD(美国)、Bio-Rad实验室股份有限公司(美国)、Cepheid(Danaher(美国)的子公司)、QIAGEN(德国)、Abbott(美国)、Hologic股份有限公司(美国)、Thermo Fisher科学股份有限公司(美国)、Siemens保健股份有限公司(德国)、Akonni生物系统股份有限公司(美国)、Biocartis(比利时)、Quantumdx集团有限公司(联合王国)、应用生物代码股份有限公司(美国)、Prominex股份有限公司(美国)、Nanomix股份有限公司(美国)、Curetis(OpGen股份有限公司的子公司)(德国) |
多功能诊断市场动态
司机
- 传染病发病率上升
传染性细菌和病毒性疾病的发病率上升影响了市场的需求,因为在综合测试中,多功能实时PCR技术和综合方法被用于传染病的分子诊断.
- 急性呼吸道综合征冠状病毒检测的监管审批增加
2020年5月,Biomérieux SA获得了FDA紧急使用授权(EUA),用于BIOFIRE RP2.1面板,用于检测22个导致呼吸道感染的病原体,包括用于COVID-19疾病的SARS-CoV-2.
监管部门,如FDA或CEmark,提供紧急使用授权(EUA),将SARS-CoV-2面板商业化,并进行检测与COVID-19疾病有关的病毒的测试,这是市场增长的动力.
机会
- 市场参与者采取的战略举措
2021年3月,F. Hoffman-La Roche Ltd收购了主要多分子诊断提供者GenMark诊断公司. 这一收购帮助了公司拓宽了Roche的分子诊断组合. 市场参与者采取的这些战略举措,包括重点部分产品的推出,正在帮助它们扩大全球覆盖面并加强其产品组合,成为市场增长的机会。
- 引进先进技术产品.
合成多子测试利用多子PCR的先进技术来检测,隔离,或放大定向核酸,以提供准确而快的诊断结果;而先进技术在45至60分钟内提供诊断结果. 因此,技术先进的产品的开发是市场增长的一个机会。
限制/挑战
- 诊断产品成本高
多功能合成测试应用利用了实时多聚酶链反应(PCR),通过放大曲线和正确值来提供结果. 综合多功能诊断中使用的仪器需要高昂的维护成本. 因此,工具的高成本是市场面临的挑战。
COVID-19 之后对交响乐的影响多功能诊断市场
COVID-19对市场产生了积极影响. 市场玩家推出不同产品来检测SARS-CoV病毒. COVID-19后,监管机构对产品的审批增加,导致市场增长增加.
最近的发展
- 2021年3月,卢明ex公司成立. 一个Diasorin公司获得了FDA紧急使用授权和CE标记,用于扩大NxTAG呼吸面板测试. 这一批准帮助了公司增加了收入.
共鸣多功能诊断市场范围
综合多功能诊断市场分为五个部分:产品和服务、感染类型、疾病、面板类型和最终用户。 这些部门的增长将有助于你分析这些行业中增长不足的部分,并为用户提供宝贵的市场概况和市场见解,帮助他们作出确定核心市场应用的战略决定。
产品和服务
- 试剂和消耗品
- 仪器、软件和附属设备
- 服务
基于产品和服务,北美合成多功能诊断市场被分入试剂和消耗品,仪器,软件和配件以及服务.
感染类型
- 维尔
- 细菌
- 寄生虫
- 鲜花
根据感染类型,北美合成多子诊断市场被分化为病毒,细菌,寄生虫和真菌.
疾病
- 呼吸道感染
- 胃炎
- 性传播感染
- 赛普西
- 脑膜炎
- 其他人员
基于疾病,北美综合多功能诊断市场被分化为呼吸道感染,胃肠炎,性传播感染,败血症脑膜炎等.
面板类型
- 呼吸小组
- GI- 进取面板
- 性传播疾病小组
- 血症治疗小组
- 脑膜炎小组
- 其他人员
根据面板类型,北美合成多功能诊断市场被分入呼吸道面板,GI-肠道面板,性病面板,血脓性面板,脑膜炎面板等.
结束用户
- 医院
- 临床实验室
- 医药和生物技术公司
- 研究所
- 其他人员
以最终用户为基础,北美合成多功能诊断市场被划分为临床实验室,医院,医药和生物技术公司,研究机构等.
共鸣多功能诊断市场 区域分析/见解
如上所述,按国家、产品和服务、感染类型、疾病、面板类型和最终用户,对综合多功能诊断市场进行分析,提供市场规模的见解和趋势。
报告涵盖的国家有美国、加拿大和墨西哥。
由于传染病发病率上升,对早期准确诊断的需求上升,预计美国综合多功能诊断市场会增长.
报告的国家部分还介绍了影响市场的因素和国内市场规章的变化,这些变化影响到市场目前和未来的趋势。 新的销售、替代销售、国家人口统计、疾病流行病学和进出口关税等数据点是用来预测个别国家市场情况的一些主要指针。 此外,由于当地和国内品牌的竞争巨大或稀少,品牌的存在和可得性及其面临的挑战,在提供国家数据的预测分析的同时,也考虑了销售渠道的影响。
共鸣多功能诊断市场共享分析
综合多功能诊断市场竞争景观提供了由竞争对手提供的细节. 详细情况包括公司概况、公司财务、创收、市场潜力、研发投资、新市场举措、沙特阿拉伯的存在、生产地点和设施、生产能力、公司优势和弱点、产品推出、产品宽度和广度、应用优势。 上述数据点仅与公司与合成多功能诊断市场相关的重点相关.
在北美合成多功能诊断市场运营的一些主要角色有:生火诊断(BioFire Consurtions)(BioMérieux SA的子公司),Seegene Inc.,Luminex Corporation. A DiaSorin公司、F. Hoffmann-La Roche有限公司、BD、Bio-Rad实验室、Cepheid(Danaher的子公司)、QIAGEN、Abbott、Hologic、Thermo Fisher科学公司、Siemens保健公司、Akonni生物系统公司、Biocartis、QuantumMDx集团有限公司、应用生物代码公司、Prominex公司、Nanomix公司、Curetis(OpGen公司的一个子公司)等。
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT AND SERVICES LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES
4.3 MARKET SHARE PER PANEL, FOR TOP 3 PLAYERS (2021)
5 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES
6.1.2 RISING ADOPTION OF MOLECULAR DIAGNOSTICS TECHNIQUES
6.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING
6.1.4 INCREASING DEMAND FOR FAST AND ACCURATE DIAGNOSTIC RESULTS
6.2 RESTRAINTS
6.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS
6.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS
6.3.2 RISING DIAGNOSTIC HEALTHCARE EXPENDITURE
6.3.3 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCTS
6.4 CHALLENGES
6.4.1 PRODUCT RECALLS
6.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS
7 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES
7.1 OVERVIEW
7.2 REAGENTS & CONSUMABLES
7.3 INSTRUMENTS, SOFTWARE & ACCESSORIES
7.4 SERVICES
8 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE
8.1 OVERVIEW
8.2 VIRAL
8.2.1 CORONAVIRUS
8.2.2 INFLUENZA VIRUS
8.2.3 ADENOVIRUS
8.2.4 RHINOVIRUS
8.2.5 ROTAVIRUS
8.2.6 OTHERS
8.3 BACTERIAL
8.3.1 PNEUMONIAE
8.3.2 BORDETELLA PERTUSSIS
8.3.3 STAPHYLOCOCCUS
8.3.4 OTHERS
8.4 PARASITES
8.5 FUNGAL
9 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE
9.1 OVERVIEW
9.2 RESPIRATORY INFECTIONS
9.3 GASTROENTERITIS
9.4 SEXUALLY TRANSMITTED INFECTIONS
9.5 SEPSIS
9.6 MENINGITIS
9.7 OTHERS
10 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE
10.1 OVERVIEW
10.2 RESPIRATORY PANEL
10.3 GI-ENTERIC PANEL
10.4 SEXUALLY TRANSMITTED DISEASE PANEL
10.5 BLOOD-SEPSIS PANEL
10.6 MENINGITIS PANEL
10.7 OTHERS
11 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICAL LABORATORIES
11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.5 RESEARCH INSTITUTES
11.6 OTHERS
12 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION
12.1 NORTH AMERICA
12.1.1 U.S.
12.1.2 CANADA
12.1.3 MEXICO
13 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMÉRIEUX SA)
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 F. HOFFMANN-LA ROCHE LTD
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 LUMINEX CORPORATION. A DIASORIN COMPANY
15.3.1 COMPANY SNAPSHOT
15.3.2 RECENT FINANCIALS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.4 CEPHEID (A SUBSIDIARY OF DANAHER)
15.4.1 COMPANY SNAPSHOT
15.4.2 RECENT FINANCIALS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.5 QIAGEN
15.5.1 COMPANY SNAPSHOT
15.5.2 RECENT FINANCIALS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 AKONNI BIOSYSTEMS, INC.
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.8 APPLIED BIOCODE, INC.
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENTS
15.9 BD
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 BIOCARTIS
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 BIO-RAD LABORATORIES, INC.
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH)
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 CURETIS (A SUBSIDIARY OF OPGEN, INC.)
15.13.1 COMPANY SNAPSHOT
15.13.2 RECENT FINANCIALS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 HOLOGIC, INC.
15.14.1 COMPANY SNAPSHOT
15.14.2 RECENT FINANCIALS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENT
15.15 MIRXES PTE LTD.
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 NANŌMIX, INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 PROMINEX INC.
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 QUANTUMDX GROUP LTD.
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENTS
15.19 SEEGENE INC.
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENTS
15.2 SIEMENS HEALTHCARE GMBH
15.20.1 COMPANY SNAPSHOT
15.20.2 RECENT FINANCIALS
15.20.3 PRODUCT PORTFOLIO
15.20.4 RECENT DEVELOPMENT
15.21 THERMOFISHER SCIENTIFIC INC.
15.21.1 COMPANY SNAPSHOT
15.21.2 RECENT FINANCIALS
15.21.3 PRODUCT PORTFOLIO
15.21.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
表格列表
TABLE 1 COST OF THE PRODUCT
TABLE 2 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA REAGENTS & CONSUMABLES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA INSTRUMENTS, SOFTWARE & ACCESSORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA SERVICES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA PARASITES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA FUNGAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA RESPIRATORY INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA GASTROENTERITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA SEXUALLY TRANSMITTED INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA SEPSIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA MENINGITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA RESPIRATORY PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA GI-ENTERIC PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA SEXUALLY TRANSMITTED DISEASE PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA BLOOD-SEPSIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA MENINGITIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA HOSPITALS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA CLINICAL LABORATORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA RESEARCH INSTITUTES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 41 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 42 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 43 U.S. VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 44 U.S. BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 45 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 46 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 47 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 48 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 49 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 50 CANADA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 51 CANADA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 52 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 53 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 54 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 55 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 56 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 57 MEXICO VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 58 MEXICO BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 59 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 60 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 61 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES IS EXPECTED TO DRIVE THE NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN THE FORECAST PERIOD
FIGURE 12 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET
FIGURE 15 TOTAL CASES OF COVID-19 IN NORTH AMERICA
FIGURE 16 TOTAL CASES OF COVID-19 IN EUROPE
FIGURE 17 NATIONAL HEALTH EXPENDITURE VS MEDICAL DEVICE EXPENDITURE, U.S., 2019
FIGURE 18 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2021
FIGURE 19 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2022-2029 (USD MILLION)
FIGURE 20 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, CAGR (2022-2029)
FIGURE 21 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, LIFELINE CURVE
FIGURE 22 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2021
FIGURE 23 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2022-2029 (USD MILLION)
FIGURE 24 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, CAGR (2022-2029)
FIGURE 25 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, LIFELINE CURVE
FIGURE 26 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2021
FIGURE 27 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2022-2029 (USD MILLION)
FIGURE 28 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, CAGR (2022-2029)
FIGURE 29 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, LIFELINE CURVE
FIGURE 30 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2021
FIGURE 31 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2022-2029 (USD MILLION)
FIGURE 32 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, CAGR (2022-2029)
FIGURE 33 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, LIFELINE CURVE
FIGURE 34 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2021
FIGURE 35 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 36 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, CAGR (2022-2029)
FIGURE 37 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2021)
FIGURE 39 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021)
FIGURE 40 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT AND SERVICES (2022-2029)
FIGURE 43 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
